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1. Introduction 
The molecular bases that account for the preferential neurodegeneration of striatal medium-
sized spiny neurons (MSNs) in Huntington’s Disease (HD) are still unknown, and different 
mechanisms have been proposed to contribute to the neurodegenerative process.  
These include mitochondrial dysfunction and metabolic impairment, transcriptional 
dysregulation, altered expression of trophic factors, dopamine toxicity, oxidative stress, and 
changes in autophagy, and huntingtin (htt) phosphorylation. In addition, excitotoxicity 
through the overactivation of N-methyl-D-aspartate (NMDA) receptors (NMDARs) has also 
been proposed to contribute to the preferential loss of these neurons (for review see 
Ehrnhoefer et al., 2011; Jin & Johnson, 2010; Perez-Navarro et al., 2006; Renna et al., 2010; 
Rosenstock et al., 2010; Weir et al., 2011). 
Some of these mechanisms are controlled by the attachment/removal of phosphate groups 
through the action of protein kinases and protein phosphatases, respectively. Therefore, 
alterations in their levels/activity in the presence of mutant htt (mhtt) can impact on cell 
survival.  
Htt is expressed in almost all tissues, has a widespread distribution in the brain, its 
expression levels are similar in control individuals and in HD patients, with no evidence of 
increased htt expression in the brain regions most affected in HD (reviewed by Han et al., 
2010). These evidences indicate that differences in mhtt expression do not contribute to the 
increased vulnerability of MSNs in HD. Conversely, several cell-type specific features 
including morphological, biochemical, and functional characteristics might play a role in 
rendering MSNs more vulnerable to the toxic effects of mhtt (Han et al., 2010). In this line, it 
is relevant in context of the present review to mention that the phosphatases calcineurin 
(also known as protein phosphatase 2B – PP2B) (Goto et al., 1987) and striatal-enriched 
protein tyrosine phosphatase (STEP) (Lombroso et al., 1991) are enriched in MSNs, 
suggesting that variations in their expression levels/activity can impact seriously in the 
function and viability of these neurons. 
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Here, we will revisit the excitotoxic hypothesis in HD through the phosphatase point of 
view, and we will also pay attention to the importance of phosphorylation in reducing the 
toxicity of mhtt. We will discuss the results obtained in both exon-1 and full-length HD 
models, and we will integrate the potential contribution of an imbalance between the 
activity of phosphatases and kinases to HD pathophysiology.  
1.1 Excitotoxicity 
Glutamate, the major excitatory neurotransmitter in the central nervous system (CNS), is 
important for neural development, synaptic plasticity, and learning and memory under 
physiological conditions. Dysregulation of glutamate levels and/or glutamate receptor 
activity can result in an overstimulation of glutamate receptors leading to cell death via 
excitotoxicity (Olney, 1969). In HD, excitotoxicity induced by overactivation of NMDARs 
has been proposed to explain the preferential neurodegeneration of MSNs (reviewed by Fan 
& Raymond, 2007; Milnerwood & Raymond, 2010; Perez-Navarro et al., 2006). Functional 
NMDARs are tetrameric structures (Laube et al., 1998) composed of two NR1 and at least 
two NR2 subunits (Ozawa et al., 1998), and the striatum is enriched in NR2B compared with 
other NR2 subunits (Landwehrmeyer et al., 1995). The presence of mhtt in striatal neurons 
leads to a number of alterations that can explain changes in the susceptibility to 
excitotoxicity. These include: (1) Selective increase of the current flowing through NMDARs 
comprising NR1/NR2B subunits (Zeron et al., 2001, 2002); (2) Changes in NMDAR 
scaffolding proteins (Jarabek et al., 2004; Sun et al., 2001; Torres-Peraza et al., 2008); (3) 
Altered phosphorylation of NMDAR subunits (Jarabek et al., 2004; Song et al., 2003) and (4) 
Imbalance between synaptic and extra-synaptic NMDARs (Milnerwood et al., 2010; 
Okamoto, 2009). In addition to alterations at the level of NMDARs, mhtt also alters 
intracellular mechanisms regulated by NMDAR stimulation, such as the activity of kinases 
and phosphatases. Calcineurin, PP1, PP2A, and STEP are phosphatases regulated by 
NMDARs stimulation (Figure 1) whose levels/activity have been shown to be altered in 
neurons expressing exon-1 or full-length mhtt (Table 1).  
1.2 Phosphorylation of htt 
Htt has several known sites of phosphorylation, all of them less phosphorylated in the 
mutant than in the wild-type protein (reviewed by Ernhoefer et al., 2011). Among the htt 
phosphorylation sites identified, serine 421 (Ser421) is the most studied and thus, the best 
characterized. This site can be phosphorylated by Akt (Humbert et al., 2002) and serum and 
glucocorticoid-induced kinase (SGK) (Rangone et al., 2004), whereas calcineurin (Pardo et 
al., 2006; Pineda et al., 2009), PP1 and PP2A (Metzler et al., 2010)  dephosphorylate it. Until 
now, phosphatases known to regulate htt phosphorylation at Ser421 have been shown to be 
altered in HD models (Table 1). Phosphorylation of Ser421 regulates htt’s toxicity (Humbert 
et al., 2002; Pardo et al., 2006), htt’s role in vesicle transport (Colin et al., 2008; Pineda et al., 
2009; Zala et al., 2008), and htt cleavage by caspases (Metzler et al., 2010; Warby et al., 2009). 
In addition, phosphorylation of htt and mhtt at Ser421 is significantly reduced in neurons 
after excitotoxic stimulation of NMDARs (Metzler et al., 2010) (Figure 1). Moreover, there 
are other Ser and threonine (Thr) residues of htt that can be phosphorylated, and all of them 
regulate its toxicity. Most of the kinases that phosphorylate these sites have been identified, 
and include IKK (Thompson et al., 2009), cyclin-dependent kinase 5 (Cdk5) (Anne et al., 
www.intechopen.com
 
Don’t Take Away My P: Phosphatases as Therapeutic Targets in Huntington’s Disease 
 
467 
2007; Luo et al., 2005), ERK1 (Schilling et al., 2006), and CK2 (Atwal et al., 2011). In contrast, 
the phosphatases acting on these residues are still unknown (reviewed by Ernhoefer et al., 
2011).  
 
Fig. 1. Regulation of phosphatases in striatal neurons by NMDAR and dopamine D1 receptor 
(DR1) stimulation. Stimulation of NMDARs activates PP2A and calcineurin, which in turn will 
activate STEP and PP1. DR1 stimulation activates PP2A, and indirectly blocks PP1 activity. 
Several pathways and targets have been omitted for simplification. PDEs: Phosphodiesterases; 
AC: Adenylyl cyclase; PKA: cAMP-dependent protein kinase; CaM: calmodulin; DARPP-32: 
dopamine- and cAMP-regulated phosphoprotein of 32 kDa 
2. Ser/Thr phosphatases 
Ser/Thr phosphatases catalyze dephosphorylation reactions on phospho-Ser and phospho-
Thr residues. They are classified into three families: protein phosphatase Mg2+-activated 
(PPM), phosphoprotein phosphatases (PPPs) and the aspartate-based phosphatases 
represented by FCP/SCP (TFIIF-associating component of RNA polymerase II CTD 
phosphatase/small CTD phosphatase). The PPM family includes PP2C, pyruvate 
dehydrogenase phosphatase, and PP2C-“like” phosphatases, and the major phosphatases in 
the PPP family are PP1, PP2A and calcineurin (reviewed by McConnell & Wadzinski, 2009). 
PP1, PP2A and calcineurin are composed of catalytic and regulatory subunits, whereas 
PP2C exists as a monomer devoid of regulatory subunits. In the brain, the activity of these 
phosphatases is regulated by the regulatory subunit, interacting partners, scaffolding 
proteins and/or specific endogenous activators/inhibitors (reviewed by Gee & Mansuy, 
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2005). These phosphatases are implicated in the regulation of excitotoxicity, synaptic 
plasticity and cell survival, and are altered in neurodegenerative disorders such as 
Alzheimer’s Disease (Ducruet et al., 2005; Iqbal & Grundke-Iqbal, 2007; F. Liu et al., 2006; 
Tian & Wang, 2002), Parkinson’s Disease (Lou et al., 2010; Wera & Neyts, 1994) and HD 
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PC12 cells overexpressing 
exon-1 mhtt 118Q 
 
HEK 293 cells 
overexpressing mhtt 
138Q and NR1/NR2B 
 
Z. L. Wu et al., 2002 
 
 
Fan et al., 2008 
Calcineurin (Xifro et al., 2009) and PHLPP1 (Saavedra et al., 2010) protein levels, and STEP mRNA 
levels (Hodges et al., 2006) are also decreased in the caudate/putamen of HD patients. HEK: human 
embryonic kidney; Q: glutamine; Tet/HD94: conditional mouse model of HD 
Table 1. Phosphatases altered in HD models. 
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Calcineurin is a Ser/Thr phosphatase activated by calcium/calmodulin, highly expressed in 
the brain, and abundant in the cytosol, and in pre-synaptic and post-synaptic terminals 
(Mansuy, 2003; Shibasaki et al., 2002). It is a heterodimer composed by a calmodulin-binding 
catalytic subunit, calcineurin A, and an intrinsic calcium-binding regulatory subunit, 
calcineurin B. The dependence on calcium distinguishes calcineurin from spontaneously 
active PP2A and from Mg2+-dependent PP2C. The binding of the calcium/calmodulin 
complex to calcineurin A with high affinity leads to the release of the auto-inhibitory 
domain from the active site and calcineurin activation. In addition to activation by calcium, 
calcineurin can also be activated by caspase- or calpain-mediated proteolysis, which 
originate a constitutively active form, insensitive to calcium/calmodulin (reviewed by A. 
Mukherjee & Soto, 2011). 
Calcineurin is the only calcium-dependent phosphatase present in neurons, which confers it 
an important role in the maintenance of cellular homeostasis, and in neuronal activity 
(Mansuy, 2003; Shibasaki et al., 2002). Calcineurin also modulates gene expression by the 
regulation of transcription factors such as the cAMP responsive element binding protein 
(CREB) and the nuclear factor of activated T-cell (NFAT) (reviewed by A. Mukherjee & Soto, 
2011). 
Calcineurin is highly expressed in the striatum, and in particular in MSNs (Goto et al., 1987). 
The participation of calcineurin in neuronal death induced by insults that elevate 
intracellular calcium levels (Ankarcrona et al., 1996; Butcher et al., 1997; Dawson et al., 1993; 
Shamloo et al., 2005; Shibasaki & McKeon 1995; Wood & Bristow 1998; H. Y. Wu et al., 2004) 
suggests that this phosphatase might be a good candidate to participate in the excitotoxic 
events associated with HD. 
The pro-apoptotic function of calcineurin has been linked to the dephosphorylation of 
selected substrates related to apoptosis, such as Bad (a pro-apoptotic Bcl-2 family member) 
(Springer et al., 2000; H. G. Wang et al., 1999), death-associated protein kinase (Shamloo et 
al., 2005; Xifro et al., 2008), cdk5 (Nishi et al., 2002) or transcription factors, such as NFAT 
(Beals et al., 1997). Importantly, calcineurin also dephosphorylates mhtt at Ser421 (Pardo et 
al., 2006). Consistent with the neuroprotective role of htt phosphorylation at Ser421 
(Humbert et al., 2002; Rangone et al., 2004; Warby et al., 2005), inhibition of calcineurin 
activity in HD neuronal cells restores htt phosphorylation levels at Ser421, and prevents 
polyglutamine (polyQ)-mediated cell death of striatal neurons (Pardo et al., 2006). 
Moreover, inhibition of calcineurin by FK506 leads to sustained phosphorylation of mhtt at 
Ser421 and reestablishes BDNF transport in rat primary neuronal cultures expressing mhtt, 
and in mouse cortical neurons from HdhQ111/Q111 mice (Pineda et al., 2009). Recently, 
calcineurin has been shown to dephosphorylate the pro-fission dynamin related protein 1 
(Cereghetti et al., 2008), which increases its mitochondrial translocation and activation, 
leading to mitochondrial fragmentation and contributing to the hypersensitivity of HD 
mitochondria to apoptosis (Costa et al., 2010). In fact, mitochondrial fragmentation can be 
prevented by genetic or pharmacological inhibition of calcineurin (Costa et al., 2010). 
Studies using primary striatal cultures from YAC transgenic mice show that NMDAR 
stimulation produces a polyQ length-dependent increase in cell death (Shehadeh et al., 2006; 
Zeron et al., 2002). These observations were extended by our studies showing that 
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STHdhQ111/Q111 cells are more susceptible to NMDA-mediated cell death than STHdhQ7/Q7 
cells, a phenomenon related to higher calcineurin A protein levels and calcineurin activity in 
mhtt knock-in striatal cells than in wild-type cells (Xifro et al., 2008). Interestingly, although 
calcineurin protein levels are similar in mouse brains containing wild-type and mhtt, 
HdhQ111/Q111 and HdhQ111/Q7 mice have significantly higher levels of calcineurin activity in 
the cortex than HdhQ7/Q7 mice (Pineda et al., 2009). In agreement with these reports showing 
increased calcineurin activity, the levels of the negative regulator of calcineurin RCAN1-1L 
are significantly down-regulated in HD brain samples (Ermak et al., 2009). Additionally, a 
dysregulation in the levels of cytosolic calcium, the calcineurin activator, was also reported 
in primary cultures from YAC128 mice (Tang et al., 2005). Calcineurin can play a toxic role 
in striatal cells expressing full-length mhtt at two different levels. High levels of calcineurin 
increase the susceptibility to excitotoxicity (Xifro et al., 2008) and, on the other hand, 
calcineurin can increase mhtt toxicity directly by dephosphorylation of its Ser421 (Ermak et 
al., 2009; Pardo et al., 2006; Pineda et al., 2009), or indirectly by regulating proteins that 
modulate mhtt toxicity, such as cdk5 (Luo et al., 2005) or calpain (Gafni et al., 2004). 
Conversely, calcineurin A mRNA levels are decreased in human HD samples (Hodges et al., 
2006). Similarly, in the striatum of R6 mouse models of HD, which express the exon-1 mhtt 
fragment, calcineurin levels are lower than in the wild-type mice striatum (Hernandez-
Espinosa & Morton, 2006; Lievens et al., 2002; Luthi-Carter et al., 2000; Xifro et al., 2009). 
Interestingly, these mice are resistant to excitotoxicity (Hansson et al., 1999, 2001; Torres-
Peraza et al., 2008). These findings suggest a dual regulation of calcineurin A expression 
during the progression of the disease, with high levels at early stages resulting in high 
susceptibility to excitotoxicity (Xifro et al., 2008), and low levels at end stages participating 
in the resistance to excitotoxic-induced cell death (Xifro et al., 2009) (Figure 2). Thus, it 
would be relevant to study whether this dual calcineurin regulation also occurs in full-
length mouse models of HD as YAC128 mice, which were reported to be more sensitive to 
excitotoxicity than controls at presymptomatic stages, but resistant to intrastriatal quinolinic 
acid (an NMDAR agonist) injection when signs of HD are obvious (Graham et al., 2009). 
Consistent with resistance to excitotoxicity (Graham et al., 2009), reduced calcineurin 
activity has been shown in the striatum of YAC128 mice at 12 months of age (Metzler et al., 
2010). 
 Studies performed in in vivo models of HD confirm the important role played by calcineurin 
in the excitotoxic-mediated cell death of striatal neurons. Calcineurin inhibition in wild-type 
mice drastically reduces quinolinic acid-induced striatal cell death (Xifro et al., 2009). 
Moreover, calcineurin activation induced by intrastriatal quinolinic acid injection in R6/1 
mice is lower than in wild-type mice (Xifro et al., 2009), which is consistent with R6/1 
animals being resistant to excitotoxicity (Hansson et al., 1999, 2001).  
However, the role of calcineurin in HD remains controversial as calcineurin inhibition has 
been reported to have protective (Costa et al., 2010; Ermak et al., 2009; Pardo et al., 2006; 
Pineda et al., 2009; Xifro et al., 2008) or worsening (Hernandez-Espinosa & Morton, 2006) 
effects in HD models. The participation of reduced calcineurin activity caused by alteration 
of calcineurin A expression in the pathophysiology of HD, and in the excitotoxic resistance 
observed in exon-1 mouse models (Xifro et al., 2009), together with the finding that 
treatment with calcineurin inhibitors accelerates the progression of the disease in R6/2 mice 
(Hernandez-Espinosa & Morton, 2006) suggest that decreased levels of calcineurin could 
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result in striatal neuronal dysfunction affecting the onset of motor alterations. However, since 
both FK506 and cyclosporine A, that does not cross the blood–brain barrier, have the same 
negative effect (Hernandez-Espinosa & Morton, 2006) the harmful effect of calcineurin 
inhibition reported in this study might be unrelated to the effect of these inhibitors in the CNS. 
Taken together, these findings suggest calcineurin as an important therapeutic target for 
HD, by its participation in excitotoxic events, as well as by its action on phosphorylated 
mhtt (Ser421) to increase toxicity. 
 
Fig. 2. Changes in striatal calcineurin levels during HD progression, and involvement in 
excitotoxicity. Results from Xifro et al. (2008) suggest that at early stages of HD calcineurin 
levels are increased and striatal neurons are more susceptible to NMDA-induced excitotoxicity. 
In contrast, at late stages, calcineurin levels are decreased and participate in the resistance of 
striatal neurons to NMDA-induced excitotoxicity (Xifro et al., 2009). CaM: calmodulin. 
2.2 Pleckstrin homology (PH) domain leucine-rich repeat protein phosphatase 
(PHLPP) 
PHLPPs constitute a subfamily within the PP2C phosphatase family. PHLPPs require Mg2+ 
and Mn2+ for their catalytic activity, and are not inhibited by traditional phosphatase 
inhibitors such as okadaic acid (Brognard et al., 2007; Gao et al., 2005). This family comprises 
three members: PHLPP1 PHLPP1and PHLPP2. PHLPP1 and PHLPP1 are splice 
variants from the same gene but have different sizes, whereas PHLPP2 is a different gene 
product and has the same domain composition of PHLPP1 (Brognard et al., 2007). PHLPP1 
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and PHLPP2 have an identical domain structure with a PH domain (sharing 63% amino 
identity) followed by a region of leucine-rich repeats, a PP2C phosphatase domain (sharing 
58% amino identity) and a C terminal PDZ ligand. In addition, PHLPP1and PHLPP2 
contain a Ras-association domain preceding the PH domain (Brognard & Newton, 2008).  
PHLPPs are expressed in the majority of human tissues and are localized in different 
cellular compartments such as cytosol, nucleus and membrane (Brognard et al., 2007; 
Brognard & Newton, 2008). In the CNS, PHLPP1 was the first identified as an mRNA that 
oscillated in a circadian rhythm-dependent manner in the suprachiasmatic nucleus (SCN) 
and was named SCOP (SCN circadian oscillatory protein) (Shimizu et al., 1999). 
PHLPP1┚/SCOP is expressed in various brain regions with a relative enrichment in 
hippocampus and cerebellum (Shimizu et al., 1999). Its expression is highly concentrated in 
neurons, and is present in nuclear, mitochondrial and cytosolic fractions (Shimizu et al., 
1999), as well as in membrane rafts (Shimizu et al., 2003). Recently, PHLPP1 and PHLPP2 
have been shown to be also expressed in hippocampal neurons (Jackson et al., 2009; 2010) 
with PHLPP1┙ as the most abundantly expressed in the adult (Jackson et al., 2010). 
Although PHLPP1 and 2 can be found in the cytosolic fraction, only PHLPP1┙ can be 
localized in the nucleus of hippocampal neurons (Jackson et al., 2010). In addition, we have 
detected PHLPP1┙ in the cortex and striatum of adult mice (Saavedra et al., 2010).  
So far, the known substrates for PHLPPs are the kinases Akt (also known as protein kinase 
B), and protein kinase C (PKC). Akt, the first identified substrate of PHLPP (Gao et al., 2005), 
is a key regulator of a wide range of cellular processes including growth, proliferation, 
metabolism, cell cycle progression, and survival. Thus, altered Akt activity has been 
associated with cancer and other disease conditions such as diabetes and neurodegenerative 
diseases (Liao & Hung, 2010). For its full catalytic activity, Akt requires phosphorylation at 
Thr308 in the activation loop and at Ser473 in the hydrophobic motif (Brazil & Hemmings, 
2001). Its activation depends on the PI3-kinase, which produces the lipid second messenger 
PtdIns-3, 4, 5-P3 (PIP3) that interacts with the PH domain of Akt and recruits the kinase to 
the plasma membrane (Sancak et al., 2008). Subsequently, the Thr308 residue is 
phosphorylated by membrane-localized 3-phosphoinositide-dependent protein kinase 1 
(PDK1) (Alessi et al., 1997; Calleja et al., 2007) and the Ser473 residue is phosphorylated by 
mTORC2 (Sarbassov et al., 2005) (Figure 3). PHLPPs specifically dephosphorylate the 
hydrophobic motif of Akt, resulting in a decrease of its activity (Gao et al., 2005), whereas 
the Thr308 site is dephosphorylated by PP2A (Bayascas & Alessi, 2005). PKC, the other 
PHLPPs substrate, consists in a Ser/Thr family of phosphorylating enzymes ubiquitously 
expressed and implicated in multiple cellular functions. There are 12 isoforms of PKC 
termed (1) calcium-dependent or classical PKCs, cPKCs (2) calcium-independent or novel 
PKCs, nPKCs, and (3) atypical PKCs, aPKCs (Amadio et al., 2006; Pearce et al., 2010). PKC 
isoforms, like Akt, are also activated by the phosphorylation of the activation segment and 
hydrophobic motif (Newton, 2003). PDK1 phosphorylates the activation segment (Dutil et al., 
1998; Le Good et al., 1998), and there is increasing evidence that mTORC2 phosphorylates the 
hydrophobic motif of at least some isoforms (Sarbassov et al., 2004; Guertin et al., 2006). The 
phosphorylation of the hydrophobic motif regulates the amplitude of PKC signaling by 
controlling the stability of the kinase. Both PHLPP1 and PHLPP2 dephosphorylate the 
hydrophobic motif of conventional and novel PKC isoforms, but not atypical PKC isoforms 
(Gao et al., 2008). This dephosphorylation induces the degradation of PKC. Thus, depletion of 
PHLPP1 or PHLPP2 leads to a robust increase in PKC levels (Gao et al., 2008).  
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Members of the AGC kinase family like p70S6K, SGK or p90RSK, which have hydrophobic 
phosphorylation motifs, are other potential substrates of PHLPPs (Brognard & Newton, 
2008). In addition to the dephosphorylation of Akt and PKC, PHLPP1/SCOP negatively 
regulates the Ras–Raf–MEK–ERK pathway by interacting directly with Ras (Shimizu et al., 
2003).  
In the CNS, PHLPPs participate in the regulation of the circadian clock (Shimizu et al., 1999), 
learning and memory (Shimizu et al., 2007), and survival (Jackson et al., 2009; 2010; 
Saavedra et al., 2010). In HD, we have shown that PHLPP1┙ is reduced in cellular as well as 
in HD mouse models, and in the putamen of HD patients (Saavedra et al., 2010). 
STHdhQ111/Q111 cells display decreased levels of PHLPP1┙ compared with STHdhQ7/Q7 cells. 
Similarly, we detected reduced levels of PHLPP1┙ in the striatum of HdhQ111/Q111 mice (at 5 
months of age), and also in the striatum of the exon-1 mouse models R6/1 (from 12 to 30 
weeks of age), R6/1:BDNF +/- (from 12 to 30 weeks of age), R6/2 (at 12 weeks of age) and 
Tet/HD94 (at 22 months of age). In addition, PHLPP1┙ levels are also decreased in the 
cortex and hippocampus of R6/1 mice at 12 and 30 weeks of age. PHLPP1 expression was 
regulated by mhtt at the transcriptional level since we also detected decreased PHLPP1 
mRNA levels in the striatum of R6/1 mice (Saavedra et al., 2010). We speculated that the 
down-regulation of PHLPP1 mRNA levels could be related with decreased activity of the 
transcription factor NF-Y, since this transcription factor is sequestered in mhtt aggregates 
(Yamanaka et al., 2008). It has recently been shown that the expression of PHLPP is 
controlled by mammalian target of rapamycin (mTOR)-dependent protein translation in 
colon and breast cancer cells (J. Liu et al., 2011). Interestingly, mTOR activity is reduced in 
HD (Ravikumar et al., 2004). Thus, it is tempting to speculate that this mechanism could also 
be involved in the down-regulation of PHLPP1┙ levels. In good correlation with decreased 
levels of PHLPP1┙ in the striatum, we observed increased phosphorylation levels of Akt 
(Ser473) and of its targets GSK3┚ (Ser9) and FoxO (Ser256). Although PHLPP1┙ levels were 
down-regulated in the cortex and hippocampus of R6/1 mice we did not observe changes in 
pAkt (Ser473) levels indicating that a reduction of PHLPP1┙ levels may not be enough to 
increase pAkt (Ser473) levels in vivo (Saavedra et al., 2010). In addition, in the striatum of 
Tet/HD94 mice, we observed that after shutting-down the expression of mhtt, PHLPP1┙ 
protein levels returned to wild-type levels but pAkt (Ser473) up-regulation was only 
partially reduced (Saavedra et al., 2010). Taken together, these results suggest that increased 
levels of pAkt is a specific mechanism taking place in striatal neurons expressing mhtt, 
which could be the sum of increased activation of kinases that phosphorylate Akt and 
decreased levels of PHLPP1┙. Since Akt activation is one of the main mechanisms to prevent 
neuronal death during injury (Chong et al., 2005), and many transgenic HD mouse models 
show little, if any, striatal cell death (Canals et al., 2004; Diaz-Hernandez et al., 2005; Garcia-
Martinez et al., 2007; Mangiarini et al., 1996; Martin-Aparicio et al., 2001), our results suggest 
that increased Akt activation could counteract mhtt toxicity.  
In addition, we showed that decreased levels of PHLPP1┙ could help to maintain high 
levels of pAkt (Ser473) in R6/1 striatum after excitotoxicity, contributing to prevent cell 
death induced by NMDARs overstimulation (Saavedra et al., 2010). 
Conversely, we found unchanged levels of PHLPP2 in the striatum in R6/1 mice at different 
stages of the disease (8, 12, 20 and 30 weeks of age), while cortical levels are decreased at 12 
and 30 weeks of age. 
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Fig. 3. PHLPP1┙ is down-regulated in HD striatum. (A) Scheme showing pathways that 
control Akt phosphorylation in wild-type cells. Akt is phosphorylated at Thr308 (T308) by 
PDK1 and dephosphorylated by PP2A, whereas the Ser473 residue (S473) is phosphorylated 
by mTORC2 and dephosphorylated by PHLPP. Once activated, Akt prevents apoptosis 
through the phosphorylation of several targets such as GSK3 and FoxO1. (B) Control of 
Akt phosphorylation in striatal cells expressing mhtt. In the presence of mhtt PHLPP1┙ 
levels are decreased and contribute to maintain high levels of Akt phosphorylated at S473 
that through increased levels of phosphorylated GSK3┚ and FoxO1 may delay striatal cell 
death. Results obtained by analyzing different brain regions suggest that mhtt could also 
affect the activation of kinases that phosphorylate Akt in the striatum, but not in other brain 
regions (Saavedra et al., 2010).  
2.3 PP1 and PP2A 
PP1 and PP2A account for the majority of Ser/Thr phosphatase activity in mammalian cells, 
and are involved in diverse cellular processes such as cell growth and proliferation, 
development, DNA replication and repair, metabolism, neural signaling, and apoptosis. The 
activity of these two phosphatases can be blocked by okadaic acid and caliculin at different 
IC50 values (Sheppeck et al., 1997). The specific oligomeric composition of PP1 and PP2A 
holoenzyme is important to control their phosphatase activity. Functional PP1 enzyme consists 
of a catalytic subunit (PP1c) and a regulatory subunit (R subunit). The PP1c associates with 
more than 50 proteins that regulate substrate specificity and subcellular localization 
(Ceulemans & Bollen, 2004; P.T. Cohen, 2002). The interaction of PP1c with its regulatory 
subunit can also influence substrate specificity. In addition, its activity is regulated by 
endogenous inhibitory proteins like inhibitor-1 (P. Cohen & Nimmo, 1978), inhibitor-2 
(Foulkes & P. Cohen, 1980), CPI-17 (Eto et al., 1997), and DARPP-32 (Walaas & Greengard, 
1991), which is highly expressed in MSNs. PP2A exists in two forms: a core dimer and a 
heterotrimeric holoenzyme. The PP2A core dimer is composed by the scaffolding A subunit 
and the catalytic C subunit and associates with a regulatory B subunit to generate the 
heterotrimeric holoenzyme, which is the predominant form of PP2A in the cell. PP2A 
regulatory B subunits are divided into four different families and play a crucial role in the 
subcellular localization of PP2A. They can also alter the overall shape of the catalytic subunit 
as well as enzyme kinetics (reviewed by McConnell & Wadzinski, 2009; Shi, 2009).  
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In the CNS, PP1 and PP2A dephosphorylate neurotransmitter receptors and proteins 
localized at the post-synaptic site, thus participating in the regulation of excitatory and 
inhibitory transmission. PP1 dephosphorylates CaMKII when bound to post-synaptic 
density, whereas soluble or synaptosomal CaMKII is deposphorylated by PP2A (Shields et 
al., 1985; Strack et al., 1997). In addition, both phosphatases regulate NMDARs-mediated 
synaptic currents in an activity-dependent manner (L. Y. Wang et al., 1994; Westphal et al., 
1999). PP1 dephosphorylates GABA receptor subunits (X. Wang et al., 2002) and down-
regulates AMPA receptor activity and trafficking by dephosphorylation of the GluR1 
subunit (reviewed by Mansuy & Shenolikar, 2006). In addition, PP1 and PP2A activity can 
promote apoptosis (reviewed by Garcia et al., 2003; Klumpp & Krieglstein, 2002). PP1 
dephosphorylates the pro-apoptotic protein Bad with its consequent activation, and PP2A 
dephosphorylates the anti-apoptotic proteins Akt and Bcl-2 inactivating them. PP2A can 
also regulate the activity of a large number of kinases, such as ERK, PKA and p38 (reviewed 
by Millward et al., 1999), all of them important to neuronal survival and function.  
Recently, the number of targets of PP1 and PP2A has been extended since both proteins 
dephosphorylate htt in situ and after excitotoxic stimulation of NMDARs (Metzler et al., 
2010; see Figure 1). Metzler and colleagues (2010) showed that NMDARs overstimulation 
induces a decrease of phtt (Ser421) in primary neurons from wild-type and YAC128 
transgenic mice. In addition, dephosphorylation of htt (Ser421) was also observed in 
YAC128 transgenic mice after quinolinic acid injection in the striatum. Dephosphorylation 
of htt after excitotoxicity seems to participate in the induction of cell death since blockade of 
PP1 and PP2A activity protects YAC128 striatal neurons from NMDA-induced cell death in 
vitro. Moreover, they showed that dopamine modulates htt phosphorylation in the striatum 
through the regulation of the PP1 inhibitor DARPP-32. These authors also observed a decrease 
in the PP1 substrate pCREB, which together with decreased levels of DARPP-32 in YAC128 
striatum suggested an altered regulation of phosphatase activity in HD. However, they could 
not detect changes in the activity of PP1 and PP2A in YAC128 mice striatum. Although these 
results point to a role of htt dephosphorylation in excitotoxic-induced cell death in the 
striatum, it remains to be shown whether inhibition of PP1 and PP2A is also neuroprotective in 
vivo. In addition, it would be interesting to investigate whether dephosphorylation of mhtt 
takes place in the striatum of YAC128 mice when they are resistant to excitotoxicity. PP2A 
protein levels have also been analyzed in the striatum of R6/1 mice. Similarly to that observed 
in YAC128 mice striatum (Metzler et al., 2010), no changes in PP2A protein levels have been 
detected in R6/1 mouse striatum at 4, 8, 12, 16 and 30 weeks of age compared with their 
littermate controls (Saavedra et al., 2010). 
3. Tyrosine phosphatases 
Tyrosine (Tyr) phosphatases, encoded by about 107 genes in the human genome (Alonso et 
al., 2004; Andersen et al., 2004), have the ability to hydrolyze p-nitrophenyl phosphate, are 
inhibited by vanadate and are insensitive to okadaic acid. They are classified into three 
groups: (1) Cytoplasmic, (2) Receptor-like, and (3) Dual specificity phosphatases, which 
dephosphorylate Ser, Thr and Tyr residues that are in close proximity. The specificity of Tyr 
phosphatases is regulated by several molecular strategies such as preferential recognition of 
phosphopeptides, cell-type and organelle-specific expression, and assembly with other 
proteins (for review see S. Paul & Lombroso, 2003; Z. Y. Zhang, 2002). These phosphatases 
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play important roles in the development and function of the CNS (Ensslen-Craig &  
Brady-Kalnay, 2004; S. Paul & Lombroso, 2003), and have been suggested to function as 
neuroprotectants. STEP, the SH2-containing Tyr phosphatases SHP1 and SHP2, and protein 
Tyr phosphatase alpha are among the protective candidates. However, protein Tyr 
phosphatase alpha and phosphatase and tensin homolog deleted from chromosome 10 
(PTEN) may also induce neurotoxicity (Gee & Mansuy, 2005). Increased Tyr 
phosphorylation has been suggested to induce neuronal cell death in cerebral ischemia 
(Ohtsuki et al., 1996; R. Paul et al., 2001) and after epileptiform activity (Chun et al., 2004; 
Sanna et al., 2000). In addition, alterations in protein Tyr phosphatases are considered to be 
involved in the etiology of neural disorders such as Alzheimer’s Disease (Kerr et al., 2006; 
Lee et al., 2004), Parkinson’s Disease (Herradon & Ezquerra, 2009) and HD (Saavedra et al., 
2011; Z. L. Wu et al., 2002). 
3.1 STEP 
STEP, encoded by the Ptpn5 gene, is a brain-specific Tyr phosphatase involved in neuronal 
signal transduction. STEP plays an important role in synaptic plasticity through the 
opposition to synaptic strengthening (Braithwaite et al., 2006a). Additionally, STEP has been 
implicated in susceptibility to cell death through the modulation of ERK1/2 signaling (Choi 
et al., 2007; Saavedra et al., 2011), while other studies suggest that STEP can play a role in 
neuroprotection through the regulation of the p38 pathway (Poddar et al., 2010; Xu et al., 
2009). The mechanism underlying the ability of STEP to regulate both pro-survival and pro-
cell death pathways has been recently elucidated (Xu et al., 2009; see details below). 
STEP is enriched in MSNs (Lombroso et al., 1991), and expressed at lower levels in the 
cortex, hippocampus and amygdala (Boulanger et al., 1995). STEP mRNA is alternatively 
spliced into several STEP isoforms (Bult et al., 1997; Sharma et al., 1995) that are 
differentially targeted to the post-synaptic density (Oyama et al., 1995), extra-synaptic and 
cytosolic compartments (Goebel-Goody et al., 2009; Xu et al., 2009). The major isoforms are 
STEP46, the cytosolic isoform, and STEP61, which is membrane-associated through the 
additional 172 amino acids in the N-terminus (Bult et al., 1997). Both isoforms are expressed 
in the striatum, whereas other brain regions only express STEP61 (Boulanger et al., 1995). 
STEP activity is regulated through phosphorylation/dephosphorylation of a Ser residue 
within its kinase interacting motif (KIM) domain. Stimulation of D1Rs activates PKA (Stoof 
& Kebabian, 1981), which phosphorylates STEP thereby inactivating it (S. Paul et al., 2000) 
(Figure 1). In contrast, stimulation of NMDARs results in the dephosphorylation and 
activation of STEP through a calcineurin/PP1 pathway (S. Paul et al., 2003; Valjent et al., 
2005) (Figure 1). Additionally, STEP activity is also regulated by proteolytic cleavage (Xu et 
al., 2009), ubiquitin-proteasome degradation (Kurup et al., 2010; S. Mukherjee et al., 2011; Xu 
et al., 2009), local translation (Y. Zhang et al., 2008), and oligomerization (Deb et al., 2011). 
Once activated, STEP dephosphorylates the glutamate receptor subunits NR2B (Braithwaite 
et al., 2006b; Pelkey et al., 2002; Snyder et al., 2005) and GluR2 (Y. Zhang et al., 2008), leading 
to their endocytosis, and the kinases ERK1/2, p38 and Fyn, thereby controlling the duration 
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The enrichment of STEP in MSNs, its role in the regulation of key substrates implicated in 
neuronal function, together with the fact that both dopaminergic and glutamatergic systems 
regulate STEP activity and are affected in HD patients and mouse models (Andre et al., 
2010; Fan & Raymond, 2007; Jakel & Maragos, 2000) prompted us to study the possible role 
of STEP in the pathophysiology of HD (Saavedra et al., 2011). In fact, previous studies 
showed decreased mRNA levels of STEP in the caudate nucleus and cortex of HD patients 
(Hodges et al., 2006), in the striatum of R6 mice (Desplats et al., 2006; Luthi-Carter et al., 
2000), and in primary striatal neurons overexpressing htt171-82Q (Runne et al., 2008). Our 
results show that R6/1 mice display reduced STEP protein levels in the striatum and cortex, 
and increased phosphorylation levels in the striatum, cortex and hippocampus. R6/2, 
Tet/HD94 and HdhQ7/Q111 mice striatum also displays decreased STEP protein and 
increased STEP phosphorylation levels (Saavedra et al., 2011). The early increase in striatal 
STEP phosphorylation levels correlates with a dysregulation of the PKA pathway that 
together with decreased calcineurin activity at later stages further contributes to an 
enhancement of STEP inactivation. Accordingly, the levels of phosphorylated ERK2 and 
p38, two targets of STEP, are increased in R6/1 mice striatum at advanced stages of the 
disease (Saavedra et al., 2011). 
HD mouse models develop resistance to excitotoxicity (Graham et al., 2009; Hansson et al., 
1999, 2001; Jarabek et al., 2004; Torres-Peraza et al., 2008), and reduced levels of calcineurin 
expression and activity can contribute to this phenomenon (Xifro et al., 2009). Stimulation of 
NMDARs activates STEP in a calcineurin-dependent manner (S. Paul et al., 2003), and 
disruption of STEP activity has been shown to lead to the activation of ERK1/2 signaling 
and to the attenuation of excitotoxic-induced cell death in the hippocampus (Choi et al., 
2007). Therefore, we wondered whether STEP acts as a calcineurin target after an excitotoxic 
stimulus to the striatum thereby contributing to the resistance to excitotoxicity observed in 
HD mouse models. After intrastriatal quinolinic acid injection, we observed higher and 
unaltered pSTEP levels, and more sustained ERK signaling in R6/1 than in wild-type mice 
suggesting that STEP inactivation could mediate neuroprotection in R6/1 striatum 
(Saavedra et al., 2011). These findings are consistent with lower calcineurin activation 
which, importantly, correlates with reduced cell death in R6/1 mice striatum after 
quinolinic acid injection (Xifro et al., 2009). In agreement with a protective role for STEP 
inactivation, blockade of STEP activity with FK-506 (an inhibitor of calcineurin) allows ERK 
activation and confers protection to hilar interneurons of the hippocampus against 
excitotoxicity (Choi et al., 2007), and intrastriatal infusion of TAT-STEP, a cell-permeable 
form, increases quinolic acid-induced cell death in the striatum (Saavedra et al., 2011). 
Conversely, low striatal STEP levels and activity (increased pSTEP levels) in R6/1 mice can 
contribute to their reduced vulnerability to excitotoxicity (Saavedra et al., 2011).  
Activation of extra-synaptic NMDARs in primary cortical neurons leads to calpain-
mediated cleavage of STEP61. This prevents STEP from binding to its substrates and 
contributes to the selective activation of extra-synaptically concentrated p38 (Xu et al., 2009). 
In contrast, synaptic NMDAR stimulation leads to the ubiquitination and degradation of 
STEP61 and ERK1/2 activation (Xu et al., 2009). We did not observe STEP61 cleavage or p38 
activation which, together with ERK2 activation, suggests a preferential stimulation of 
synaptic NMDARs in our model (Saavedra et al., 2011). This is relevant because an 
imbalance between synaptic and extra-synaptic NMDARs has been shown to occur in 
YAC128 mice (Milnerwood et al., 2010; Okamoto et al., 2009). However, these mice develop 
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resistance to excitotoxicity with age (Graham et al., 2009), and those studies were performed 
in vulnerable mice. Thus, it is likely that increased extra-synaptic NMDARs during 
excitotoxicity-sensitive stages might increase STEP61 cleavage to STEP33 enabling higher 
activation of p38 than in wild-type mice. In contrast, in resistant mice other mechanisms 
should regulate striatal cell survival in response to excitotoxicity and, according with our 
findings, STEP regulation of ERK activity seems to play an important role (Saavedra et al., 
2011). 
 
Fig. 4. Regulation of STEP levels and activity in the R6/1 mouse striatum during the 
progression of the disease. The presence of mhtt in the striatum alters this system at 
different levels: (1) At early stages mhtt induces a down-regulation of STEP mRNA and 
protein levels, and a dysregulation of the PKA pathway that correlates with increased STEP 
phosphorylation. (2) At late stages, calcineurin activity is also reduced further inactivating 
STEP with a consequent increase of pERK2 levels (p-p38 levels and possibly other non-
analyzed STEP targets). Decreased STEP activity, through the regulation of its targets, could 
be involved in the development of resistance to excitotoxicity in R6/1 mice striatum. 
(scheme from Saavedra et al., 2011).  
STEP has recently been implicated in the etiology of Alzheimer’s Disease (Kurup et al., 2010; 
Snyder et al., 2005; Y. Zhang et al., 2010) but the alterations in the STEP pathway found in 
HD mouse models are specific because STEP protein levels and activity, in contrast to that 
observed in Alzheimer’s Disease, are reduced in HD (Saavedra et al., 2011). Since the genetic 
reduction of STEP levels reverses cognitive and cellular deficits in Alzheimer’s Disease mice 
(Y. Zhang et al., 2010), the modulation of STEP levels might be a good therapeutic strategy 
in HD. Nevertheless, the possibility of restoring STEP expression in HD is presently 
hampered by the lack of data about the regulation of STEP gene expression. 
3.2 MAP kinase phosphatases (MKPs) 
MKPs are intracellular dual Tyr phosphatases with an expression restricted to different 
subcellular compartments (S. Paul & Lombroso, 2003). Some of these MKPs, such as MKP-1, 
-2, -3 and -X, have been shown to be expressed in the brain with a specific distribution and 
different substrate preferences. MKP-1 is expressed in the cortex, thalamus, striatum and 
cerebellum with the following substrate specificity: p38>JNK/SAPK>>ERK (Boschert et al., 
1998; Franklin & Kraft, 1997; Misra-Press et al., 1995; Takaki et al., 2001). MKP-2 is localized 
in the prefrontal cortex, hippocampus and cerebellum and inactivates ERK and JNK/SAPK 
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with the same specificity, but it can also act on p38 (Chu et al., 1996; Dwivedi et al., 2001; 
Groom et al., 1996; Misra-Press et al., 1995). MKP-3 is detected in the cerebral cortex, 
striatum and hippocampus acting preferentially on ERK, but it can also inactivate 
JNK/SAPK and p38 with the same specificity (Boschert et al., 1998; Muda et al., 1996a,b; 
Takaki et al., 2001). Finally, MKP-X is expressed throughout the brain and acts preferentially 
on ERK, although it can also dephosphorylate p38 (Boschert et al., 1998; Dowd et al., 1998; 
Muda et al., 1996b; Shin et al., 1997).  
Although they are expressed in the brain, their role in neuronal function is not well 
established. MKP-1 increases in rat brain after limbic epilepsy (Gass et al., 1996) and, 
together with MKP-3, upon cerebral hypoxia in neuronal nuclei of newborn piglets (Mishra 
& Delivoria-Papadopoulos, 2004). Moreover, both MKP-1 and -3 play important roles in 
neural plastic modifications after drug exposure (Takaki et al., 2001), whereas MKP-2 is 
increased in postmortem brains of suicide subjects with major depression (Dwivedi et al., 
2001). Recently, it has been shown that MKP-1 controls axon branching of cortical neurons 
in response to the trophic factor BDNF (Jeanneteau et al., 2010). In addition, in PC12 cells, 
oxidative stress and hypoxia increase MPK-1 expression, while trophic factor treatment up-
regulates both MKP-1 and -3 (Camps et al., 1998; Keyse & Emslie, 1992; Seta et al., 2001). 
Thus, regulation of MPKs seems to be important not only after brain injury, but also during 
development.  
In a stable PC12 cell line expressing truncated mhtt with 118Q, Z. L. Wu and colleagues 
(2002) showed that MKP-1 and -3 mRNA levels, and MKP-1 protein levels, were increased 
at different time points after mhtt expression. In good correlation with changes in MKPs 
levels, they observed a substantial reduction of ERK1/2 phosphorylation. Interestingly, 
treatment with sodium orthovanadate and bp V (pic), two general Tyr phosphatase 
inhibitors, rescues cells from polyQ-induced cell death suggesting that these phosphatases 
are involved in mhtt-induced toxicity (Z. L. Wu et al., 2002). In HEK 293 cells transfected 
with NR1/NR2B and htt containing 138Q, MKP-2 has been shown to be reduced in the 
soluble fraction and increased in the particulate-derived fraction when compared with cells 
expressing htt with 15Q (Fan et al., 2008). However, the mechanism underlying this 
redistribution and the physiological significance of this event are presently unknown.  
4. Conclusion 
Understanding the pathways by which mhtt causes neuronal dysfunction and death is 
essential to develop efficient treatments for HD. Great progress has been made over the last 
years in highlighting the molecular mechanisms affected by mhtt. Here, we have reviewed 
the existing data about changes in the expression and regulation of phosphatases in HD 
models and human HD brain. From these results, it is becoming increasingly clear that 
alterations in phosphatases are involved in the pathogenesis of HD. So far, the phosphatases 
analyzed participate in the regulation of excitotoxicity and neuronal survival (through the 
regulation of the PI3K/Akt pathway, ERK2 and/or htt phosphorylation). In mouse models, 
most of them are decreased, which seems to be a compensatory mechanism induced in 
response to mhtt expression in order to prevent neuronal cell death. However, how this 
might translate to humans is still unknown as we cannot follow the disease from the 
beginning, and analysis of phosphatase levels and activity can be performed only at late 
stages of the disease. We believe that the regulation of phosphatases is a new and promising 
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approach to treat HD. Therefore, our future challenge is to develop novel tools to treat HD 
based on these findings. In addition, phosphatases are also involved in the pathogenesis of 
other neurodegenerative disorders, and ongoing investigations of disease mechanisms in 
HD can also provide new therapeutic approaches to Parkinson’s or Alzheimer’s Diseases. 
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